Vaccines (Sep 2021)

Potential Adjuvant Therapeutic Effect of <i>Lactobacillus plantarum</i> Probio-88 Postbiotics against SARS-COV-2

  • Irfan A. Rather,
  • Sy-Bing Choi,
  • Majid Rasool Kamli,
  • Khalid Rehman Hakeem,
  • Jamal S. M. Sabir,
  • Yong-Ha Park,
  • Yan-Yan Hor

DOI
https://doi.org/10.3390/vaccines9101067
Journal volume & issue
Vol. 9, no. 10
p. 1067

Abstract

Read online

In response to the ongoing COVID-19 pandemic, the global effort to develop high efficacy countermeasures to control the infection are being conducted at full swing. While the efficacy of vaccines and coronavirus drugs are being tested, the microbiome approach represents an alternative pathophysiology-based approach to prevent the severity of the infection. In the current study, we evaluated the action of a novel probiotic Lactobacillus plantarum Probio-88 against SARS-COV-2 replication and immune regulation using an in vitro and in silico study. The results showed that extract from this strain (P88-CFS) significantly inhibited the replication of SARS-COV-2 and the production of reactive oxygen species (ROS) levels. Furthermore, compared with infected cells, P88-CFS treated cells showed a significant reduction in inflammatory markers such as IFN-α, IFN-β, and IL-6. Using an in silico molecular docking approach, it was postulated that the antiviral activity of L. plantarum Probio-88 was derived from plantaricin E (PlnE) and F (PlnF). The high binding affinity and formation of hydrogen bonding indicated that the association of PlnE and PlnF on SARS-COV-2 helicase might serve as a blocker by preventing the binding of ss-RNA during the replication of the virus. In conclusion, our study substantiated that P88-CFS could be used as an integrative therapeutic approach along with vaccine to contain the spread of the highly infectious pathogen and possibly its variants.

Keywords